Your session is about to expire
← Back to Search
Antifungal
Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis
Phase 1
Waitlist Available
Research Sponsored by SATO Pharmaceutical Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 days
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a medicated solution with 10% Luliconazole applied daily for about a month in adults with a toenail fungal infection. The solution aims to kill the fungus causing the infection. Luliconazole is a new treatment being developed in the USA for skin and nail infections.
Eligible Conditions
- Toenail Fungus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 36 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
PK parameters for the systemic absorption of luliconazole - AUC0-24h
PK parameters for the systemic absorption of luliconazole - AUC0-∞
PK parameters for the systemic absorption of luliconazole - Cmax
+5 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: SKX-16 (Luliconazole 10% Solution)Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
SATO Pharmaceutical Co., Ltd.Lead Sponsor
1 Previous Clinical Trials
134 Total Patients Enrolled
Brent Clary, CCRCStudy ChairClinical Research Coordinator J&S Studies, Inc.